Koji Shinkai

High-Frequency Repetitive Transcranial Magnetic Stimulation Improves Refractory Depression by Influencing Catecholamine and Brain-Derived Neurotrophic Factors

Toru Yukimasa, Reiji Yoshimura, Akira Tamagawa et al. · Pharmacopsychiatry · 2006 · 150 citations

Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6

Shingo Kakihara, Reiji Yoshimura, Koji Shinkai et al. · International Clinical Psychopharmacology · 2005 · 96 citations

Psychotropic Medication, Psychopharmacology, Neuropsychiatry +20

Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients

Reiji Yoshimura, Hikaru Hori, Nobuhisa Ueda et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 2007 · 56 citations

Schizophrenic Patients, Psychiatry, Psychotic Disorder +7

Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia

Reiji Yoshimura, Nobuhisa Ueda, Koji Shinkai et al. · International Clinical Psychopharmacology · 2003 · 51 citations

Neuropsychology, Psychotropic Medication, Psychopharmacology +17

Associations Between Baseline Plasma MHPG (3-methoxy-4-hydroxyphenylglycol) Levels and Clinical Responses With Respect to Milnacipran Versus Paroxetine Treatment

Koji Shinkai, Reiji Yoshimura, Nobuhisa Ueda et al. · Journal of Clinical Psychopharmacology · 2004 · 42 citations

Psychopathology, Psychopharmacology, Pharmacotherapy +18